On August 2nd, 2024 Oncolytics Biotech Inc. implemented a U.S.-only at-the-market offering by way of MJDS shelf prospectus for a US$50 million.
McCarthy Tétrault advised Oncolytics Biotech Inc. with a team led by Michael Bennett that included Mike Hegedus and Taylor Page.
